Radium-223
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Castrate Resistant Prostate Cancer
Conditions
Castrate Resistant Prostate Cancer, Bone Metastases
Trial Timeline
Apr 1, 2017 → Jun 29, 2020
NCT ID
NCT04995614About Radium-223
Radium-223 is a pre-clinical stage product being developed by Bayer for Castrate Resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04995614. Target conditions include Castrate Resistant Prostate Cancer, Bone Metastases.
What happened to similar drugs?
1 of 4 similar drugs in Castrate Resistant Prostate Cancer were approved
Approved (1) Terminated (1) Active (2)
❌custirsen sodium + isotonic, 0.9% sodium chloride + docetaxel + cabazitaxel + prednisoneAchieve Life SciencesPhase 3
Hype Score Breakdown
Clinical
3
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04037358 | Phase 2 | Completed |
| NCT04995614 | Pre-clinical | Completed |
| NCT03002220 | Phase 2 | Completed |
Competing Products
20 competing products in Castrate Resistant Prostate Cancer